Lung cancer

TAS6417-201

An Open-Label, Phase 2b, Global Multicenter Cohort Trial to;Assess the Safety and Efficacy of Zipalertinib in Patients;with Locally Advanced or Metastatic Non-Small Cell Lung;Cancer with Exon 20 Insertion and Uncommon/Single or;Compound Epidermal Growth Factor Receptor Mutations.

Open at Paris since : 05/04/2024
Target : Adult
Phase : Phase II

Trial description

To evaluate the objective response;rate (ORR) of zipalertinib in patients;who have locally advanced or;metastatic NSCLC with EGFR;ex20ins mutations or other;uncommon single or compound;EGFRmt.;À ORR, defined as the proportion of patients experiencing a best;overall confirmed response of CR or PR, per Response Evaluation;Criteria in Solid Tumors, Version 1.1 (RECIST 1.1).

Url of the trial

Main investigator

NICOLAS GIRARD

Professeur - Médecin

Contact